•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.INOVIO to Participate in Upcoming Investor Conferences
Inovio Pharmaceuticals Q3 Earnings Call Highlights
Inovio Pharmaceuticals, Inc. (INO) Q3 2026 Earnings Call Transcript
INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights
INOVIO Announces Pricing of Approximately $75 Million Public Offering
INOVIO Announces Proposed Public Offering of its Common Stock
Inovio: Upgrading To 'Buy' On Voceryq Accelerated Approval RRP And Competitive Advantages
4 Biotech Stocks Seeing Unusual Options Volume Today
INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
INOVIO to Participate in Upcoming Scientific Conferences
Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP Transcript
Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product
Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket
INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science
Critical Survey: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)
Bet on 4 Top-Ranked Stocks With Rising P/E
Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP